Mr. Erez Tetro reports

VVT MED ANNOUNCES RECEIPT OF MANAGEMENT CEASE TRADE ORDER

Further to the news release dated April 17, 2026, regarding VVT Med Inc.'s application to the B.C. Securities Commission for a temporary management cease trade order to be imposed in respect of its delay in filing its annual financial statements, management's discussion and analysis, and related officer certifications for the financial year ended Dec. 31, 2025, the BCSC has granted the MCTO.

The MCTO does not affect the ability of shareholders who are not employees or insiders of the company to trade their securities of the company. The MCTO prohibits the chief executive officer and the chief financial officer of the company from trading in securities of the company for so long as the required filings are not filed. Additionally, for so long as the required filings are not filed, the company will not, directly or indirectly, issue securities or acquire securities from an insider or employee of the company except in accordance with legally binding obligations to do so existing as of May 1, 2026.

As previously disclosed, the delay in filing the required filings is due to external circumstances beyond the company's control. While the company has worked diligently to meet its continuous disclosure obligations, the continuing armed conflict in the Middle East has caused significant disruptions to the operational and administrative processes required to finalize the company's annual reporting and audit. These regional challenges, which include restricted access to essential resources and personnel availability at the company and various service providers in Israel, have necessitated an extension of the reporting timeline.

The company remains committed to completing the filing as soon as practicable. The company wishes to clarify that this delay is administrative in nature and does not arise from any disagreement with its auditor, and there are no material uncertainties regarding the company's financial position. The company anticipates that it will be in a position to remedy the default by filing the required filings on or before June 29, 2026. The MCTO will be in effect until the required filings are completed.

In accordance with National Policy 12-203 (Cease Trade Orders for Continuous Disclosure Defaults), the company will provide biweekly status updates by way of news releases for so long as the required filings remain outstanding. The company does not anticipate any additional specified defaults under NP 12-203. The company confirms that, as of the date of this news release, there is no insolvency proceeding against it and there is no other material information concerning the affairs of the company that has not been generally disclosed.

Other than as disclosed herein, the company is up to date in its filing obligations.

About VVT Med Inc.

VVT is the only Food and Drug Administration-cleared, stand-alone company offering non-thermal, non-tumescent varicose vein treatment technology. VVT's catheter-based technologies, ScleroSafe and V-Block enable safe, office-based procedures with no anesthesia or downtime. Addressing the widest range of vein diameters, VVT's solutions empower physicians to treat both the medical and aesthetic aspects of vein disease through a cost-efficient, simultaneous sclerosant injection and blood aspiration process. The company's patented technology portfolio includes 55 patents from 14 patent families across 20 countries, providing broad global intellectual property protection through 2038.

We seek Safe Harbor.